""Their patents are years away from commercialization and...

First 127 Last

Share
Profile

Follow
Fantasyboy

4,190 Posts.

2950

31/08/20

23:10

Post #: 46970850
Share

Originally posted by regalinvestor: ↑

Mate, I was so ready to let everything go and move on. But since you insist, I guess I'll bathe in my own vomit once again, as you so aptly put it.

Outrageous? For what? For not supporting your agenda, for providing a different and plausible opinion? How can a HC post, possibly qualify as defamation. Allow me to go into detail then as someone with a background in finance and justify why I wrote what I did earlier.

Let's go back a bit. NVX's meteoric rise in early June was triggered by a rumour and then a subsequent 'small caps' news article (released on June 3) which told people that there was an impending Tesla + Novonix partnership (which will likely not originate, come battery day). This led the stock to go from $0.41 to $1.43 over the course of 2 days. Recent share interest is mainly due to the impending battery day and Tesla's own stock price increase.

Fundamentally, the company sells battery testing equipment and operates at a whopping $557 million market cap, with only $3.6 million in annual revenue, and is cash flow negative, burning through cash at a rate of $5.5 million per year through operating expenditures alone. Executives pay themselves very handsomely in salary and options.

Their patents are years away from commercialization and production, and the organisation keeps their share price propped up by making interview appearances and releasing frequent announcements that are overly optimistic and using buzzwords like 'million mile battery' 'to attract new investors, as their plan to keep themselves operating for the next few years will rely heavily on capital raising and dilution.

So forgive me, for making the assumption that one of the director's may have believed the company was slightly overvalued and wanted to cash out some funds (while also posting some Tesla pictures on his LinkedIn the day before for a small 14% premium on his capital gains).

Expand

""Their patents are years away from commercialization and production"

Nope, they start delivery this October.
So that's one more lie from you.

NVX Price at posting: $1.60 Sentiment: Hold Disclosure: Held
8 Upvote

0 Great analysis

Reply

Top Stories

SPR

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

PL3

Patagonia looks to raise $2.15M for South American exploration and development

MSB

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

OCC

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

SRL

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

There are more pages in this discussion • 10 more messages in this thread...

First 127 Last

Add NVX (ASX) to my watchlist

(20min delay)
Last 69.0¢		Change 0.005(0.73%)		Mkt cap ! $337.4M

Open	High	Low	Value	Volume
69.0¢	70.0¢	68.5¢	$300.0K	432.8K

Buyers (Bids)

No.	Vol.	Price($)
9	132316	68.5¢

Sellers (Offers)

Price($)	Vol.	No.
69.0¢	7736	1

View Market Depth

No.	Vol.	Price($)
9	132316	0.685
11	159656	0.680
4	16715	0.670
4	47968	0.660
4	27326	0.655

Price($)	Vol.	No.
0.690	7736	1
0.700	70127	5
0.705	6100	1
0.710	19286	2
0.715	10000	1

Last trade - 16.10pm 09/07/2024 (20 minute delay)

NVX (ASX) Chart

""Their patents are years away from commercialization and...

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Patagonia looks to raise $2.15M for South American exploration and development

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

""Their patents are years away from commercialization and...

Top Stories

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Patagonia looks to raise $2.15M for South American exploration and development

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News